DailySpaceElsoft Research Berhad
0090 · Main Market主板（Main Market） · annual reports 2023 to 2025, 982 entries read2023 至 2025 年报，共读出 982 条
The company这家公司
Elsoft Research Berhad designs and manufactures automated test equipment (ATE) for the semiconductor, optoelectronics and medical devices industries, and is developing test solutions for metalens technology.Elsoft Research Berhad 为半导体、光电子和医疗器械行业设计和制造自动化测试设备（ATE），并正在开发超透镜技术测试方案。
Source: annual report 2023, page 13; annual report 2024, page 13; annual report 2025, pages 12, 14.出处：2023 年年报第 13 页；2024 年年报第 13 页；2025 年年报第 12、14 页。
In 2025, Malaysia accounted for RM6,432,270 of revenue, Asia outside Malaysia brought RM1,429,484, and the United States contributed RM565,706.2025 年，马来西亚占营业额 RM6,432,270，马来西亚以外的亚洲地区贡献 RM1,429,484，美国贡献 RM565,706。
Source: annual report 2025, page 132.出处：2025 年年报第 132 页。
The customer profile has shifted: in 2023, a lighting solutions MNC and its suppliers accounted for approximately 39% of total turnover (Customer A bringing RM6,237,587), while in 2025 a medical devices corporation accounted for approximately 50% of group turnover (Customer B bringing RM4,176,000).客户结构发生变化：2023 年，一家照明方案跨国公司及其供应商约占总营业额的 39%（客户 A 贡献 RM6,237,587），而 2025 年一家医疗器械公司约占集团总营业额的 50%（客户 B 贡献 RM4,176,000）。
Source: annual report 2023, pages 16, 129; annual report 2025, pages 15, 132.出处：2023 年年报第 16、129 页；2025 年年报第 15、132 页。
The siblings Tan Cheik Eaik, Tan Ah Lek, Tan Ai Jiew and Tan Cheik Kooi are major or substantial shareholders and/or directors. As at 2023, Tan Cheik Eaik held 159,389,440 shares (23.02%), Tan Ai Jiew held 85,616,600 shares (12.36%), Koay Kim Chiew held 74,020,060 shares (10.69%), Tan Ah Lek held 63,434,498 shares (9.16%), and Tan Cheik Kooi held 48,534,360 shares (7.01%).Tan Cheik Eaik、Tan Ah Lek、Tan Ai Jiew 及 Tan Cheik Kooi 四兄弟姐妹为主要或大股东及／或董事。截至 2023 年，Tan Cheik Eaik 持有 159,389,440 股（23.02%），Tan Ai Jiew 持有 85,616,600 股（12.36%），Koay Kim Chiew 持有 74,020,060 股（10.69%），Tan Ah Lek 持有 63,434,498 股（9.16%），Tan Cheik Kooi 持有 48,534,360 股（7.01%）。
Source: annual report 2023, pages 6, 62.出处：2023 年年报第 6、62 页。
Pledged securities accounts in the thirty largest shareholders include accounts for Tay Cheng Koon with 9,021,800 shares (1.33% in 2025) and Ooi Keng Thye with 4,810,500 shares (0.71% in 2025). On the board, Madam Tan Ai Jiew retired on 7 June 2024. Dato' Dr Chong Eng Keat @ Teoh Eng Keat retired as Chairman on 29 May 2025, and Ir. Academician Emeritus Professor Tan Sri Dato' Seri Dr. Chuah Hean Teik was appointed Chairman of the Board.前三十大股东中的质押证券账户包括 Tay Cheng Koon 的账户持有 9,021,800 股（2025 年占 1.33%）和 Ooi Keng Thye 的账户持有 4,810,500 股（2025 年占 0.71%）。董事会方面，Madam Tan Ai Jiew 于 2024 年 6 月 7 日退任。Dato' Dr Chong Eng Keat @ Teoh Eng Keat 于 2025 年 5 月 29 日卸任主席，Ir. Academician Emeritus Professor Tan Sri Dato' Seri Dr. Chuah Hean Teik 接任董事会主席。
Source: annual report 2024, page 39; annual report 2025, pages 46, 134.出处：2024 年年报第 39 页；2025 年年报第 46、134 页。
Revenue by destination, 20252025 年按目的地划分的营业额
Source: annual report 2025, page 132.出处：2025 年年报第 132 页。
Major events大事记
Source: annual report 2023, pages 13, 67.出处：2023 年年报第 13、67 页。
Source: annual report 2023, pages 74, 110.出处：2023 年年报第 74、110 页。
Source: annual report 2023, page 40.出处：2023 年年报第 40 页。
Source: annual report 2024, page 39.出处：2024 年年报第 39 页。
Source: annual report 2024, pages 13, 98.出处：2024 年年报第 13、98 页。
Source: annual report 2024, pages 67, 72.出处：2024 年年报第 67、72 页。
Source: annual report 2025, page 46.出处：2025 年年报第 46 页。
Source: annual report 2025, page 77.出处：2025 年年报第 77 页。
Source: annual report 2025, page 77.出处：2025 年年报第 77 页。
Revenue and profit营业额与盈利
Liabilities and cash负债与现金
20232023 年
In 2023, the group received RM34,200,000 of proceeds from the disposal of an investment property. On 6 June 2023, the company acquired 100% of Xyrius Solutions Sdn. Bhd. for RM9,300,000, paying RM500,000 in cash and RM8,800,000 through the issuance of 16,000,000 new ordinary shares. Capital spending on property, plant and equipment was RM47,000, while RM23,526,624 was placed into other investments. Dividends paid totalled RM20,454,988, and 100,000 shares were repurchased for RM50,743.2023 年，集团收回脱售投资产业的款项 RM34,200,000。2023 年 6 月 6 日，公司以 RM9,300,000 收购 Xyrius Solutions Sdn. Bhd. 100% 股权，以 RM500,000 现金及发行 16,000,000 股新普通股支付 RM8,800,000。添置物业、厂房与设备的资本支出为 RM47,000，另有 RM23,526,624 投入其他投资。已付股息总额为 RM20,454,988，并斥资 RM50,743 回购了 100,000 股股票。
Source: annual report 2023, pages 73, 74, 84, 88, 110, 111.出处：2023 年年报第 73、74、84、88、110、111 页。
20242024 年
In 2024, the company disposed of its 100% interest in Xyrius Solutions Sdn. Bhd. on 17 December 2024 for RM7,320,000 in cash, recognising a loss on disposal of RM1,744,443. The group acquired a 31.25% equity interest in associate Ento Feed Sdn. Bhd. for RM156,255 and provided a loan of RM1,443,745 to the associate at 8% interest per annum. Capital expenditure was RM216,450. Dividends paid were RM20,449,102, and the company repurchased 16,204,300 shares for RM7,114,791.2024 年，公司于 2024 年 12 月 17 日以 RM7,320,000 现金脱售其持有的 Xyrius Solutions Sdn. Bhd. 100% 股权，确认脱售亏损 RM1,744,443。集团以 RM156,255 收购联营公司 Ento Feed Sdn. Bhd. 31.25% 股权，并向该联营公司提供按年利率 8% 计息的 RM1,443,745 贷款。资本支出为 RM216,450。已付股息为 RM20,449,102，公司斥资 RM7,114,791 回购了 16,204,300 股股票。
Source: annual report 2024, pages 71, 72, 78, 84, 98, 102.出处：2024 年年报第 71、72、78、84、98、102 页。
20252025 年
In 2025, profit before tax was RM5,510,070. Other income reached RM10.378 million, mainly from a fair value gain on other investments of RM6,461,429. An impairment loss of RM1.444 million was recognised on the loan provided to associate Ento-Feed. Capital expenditure on property, plant and equipment was RM226,005. No shares were repurchased, and no dividend was paid during the year, though an interim dividend of RM0.005 per share amounting to RM3,381,262 was declared and payable at year end.2025 年，税前盈利为 RM5,510,070。其他收入达 RM10.378 million，主要来自其他投资公允价值收益 RM6,461,429。向联营公司 Ento-Feed 提供的贷款确认了 RM1.444 million 的减值亏损。添置物业、厂房与设备的资本支出为 RM226,005。年内未回购股票，亦未支付股息，但已宣派并在年末应付每股 RM0.005 的中期股息，共计 RM3,381,262。
Source: annual report 2025, pages 13, 67, 73, 90, 119.出处：2025 年年报第 13、67、73、90、119 页。
Across the three years三年合看
The 2025 report shows no debt. Cash was deployed into unit trusts and bond funds, which stood at RM72,375,192 at end 2024. A total of 17,920,260 shares were repurchased and held as treasury shares at a cumulative cost of RM8,532,305. Dividends of RM20,454,988 in 2023 and RM20,449,102 in 2024 were paid out.2025 年报显示集团没有债务。现金被配置于单位信托和债券基金，截至 2024 年末达 RM72,375,192。累计回购并持作库存股的股份达 17,920,260 股，总成本为 RM8,532,305。2023 年和 2024 年分别支付了 RM20,454,988 及 RM20,449,102 的股息。
Source: annual report 2024, pages 84, 105; annual report 2025, pages 71, 72, 76, 90.出处：2024 年年报第 84、105 页；2025 年年报第 71、72、76、90 页。
Still to be spent尚未支出的承诺
From the RM38,000,000 proceeds of the land disposal completed in November 2022, RM14.24 million allocated for business or production expansion remained unutilised, with the timeframe extended to 3 November 2026. The RM7.239 million of net proceeds from the disposal of Xyrius allocated for general working capital was fully utilised by the end of 2025.2022 年 11 月完成的土地脱售所得 RM38,000,000 中，分配用于业务或生产设施扩建的 RM14.24 million 仍未动用，期限已延长至 2026 年 11 月 3 日。脱售 Xyrius 所得并分配用于一般营运资金的 RM7.239 million 净额已在 2025 年底前全数动用完毕。
Source: annual report 2025, pages 69, 70.出处：2025 年年报第 69、70 页。
Four years of figures四年数字
Group figures, in RM, as printed in the statements.集团数字，单位令吉，照财务报表所印。
| Group集团 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| RM令吉 | RM令吉 | RM令吉 | RM令吉 | |
| Revenue营业额 | 28,094,636 | 16,072,778 | 13,887,125 | 8,427,460 |
| Profit before tax税前盈利 | 47,222,066 | 7,775,844 | 2,806,492 | 5,510,070 |
| Profit for the financial year attributable to equity holders of the parent母公司持有人应占财政年度盈利 | 42,969,102 | 7,024,194 | 2,207,372 | 5,050,017 |
| Purchase of property, plant and equipment添置物业、厂房与设备 | (138,893) | (47,000) | (216,450) | (226,005) |
| Dividends paid已付股息 | (13,526,658) | (20,454,988) | (20,449,102) | 0 |
| Repurchase of treasury shares回购库存股 | (279,332) | (50,743) | (7,114,791) | 0 |
| Provision for repair and other services维修及其他服务拨备 | 2,006,023 | 965,717 | 860,340 | 653,470 |
| Total liabilities总负债 | 12,459,903 | 5,982,141 | 4,824,837 | 8,037,091 |
| Cash and bank balances现金与银行结余 | 6,667,230 | 3,928,039 | 2,551,238 | 3,268,032 |
| TOTAL EQUITY AND LIABILITIES权益与负债总额 | – | 140,392,442 | 113,827,937 | 118,614,167 |
On a computer, hover over a figure for the report and page it is printed on.在电脑上把鼠标移到数字上，可看到它印在哪份年报的哪一页。
Said and done说过的与做到的
| What the reports said年报说要做的 | What later reports show之后年报显示的 | Status状态 |
|---|---|---|
| Contract liabilities for FYE 2023 were expected to be fulfilled and recognised in FYE 2024.2023 财政年度的合约负债预计将在 2024 财政年度履行并确认为收入。 | In 2024, contract liabilities decreased by 36.6% from RM0.985 million to RM0.624 million as the majority brought forward were fulfilled and recognised.2024 年，合约负债因大部分结转余额已履行并确认而减少 36.6%，由 RM0.985 million 降至 RM0.624 million。 Source: annual report 2023, page 14; annual report 2024, page 13.出处：2023 年年报第 14 页；2024 年年报第 13 页。 | Fulfilled已履行 |
| Proceeds of RM14.24 million from the land disposal allocated for business or production expansion were scheduled for utilisation by 3 November 2026.土地脱售所得中分配用于业务或生产设施扩建的 RM14.24 million 款项预定于 2026 年 11 月 3 日前动用完毕。 | In 2025, the same RM14.24 million remained unutilised, with expansion spending standing at 3.4%.2025 年，相同的 RM14.24 million 款项仍未动用，扩建支出比例仍为 3.4%。 Source: annual report 2024, page 66; annual report 2025, page 69.出处：2024 年年报第 66 页；2025 年年报第 69 页。 | Unchanged维持未变 |
| Entopia expected to see a positive impact on visitor arrivals by the end of 2025 following the introduction of Entopia by Night.在推出 Entopia by Night 后，Entopia 预计到 2025 年底入场游客人数将出现积极变化。 | In 2025, international arrivals increased by 11% while domestic arrivals decreased by 5%, and the company noted that Entopia by Night required a longer duration to establish.2025 年，国际游客人数增长 11%，而国内游客减少 5%，公司指出 Entopia by Night 需要更长时间来建立市场认知。 Source: annual report 2024, page 14; annual report 2025, page 15.出处：2024 年年报第 14 页；2025 年年报第 15 页。 | Partly increased部分增长 |
| Proceeds of RM7.239 million from the disposal of Xyrius were allocated to general working capital to be used within 24 months.脱售 Xyrius 所得中分配用于一般营运资金的 RM7.239 million 预定在 24 个月内使用。 | In 2025, the RM7.239 million was 100% utilised for general working capital.2025 年，该笔 RM7.239 million 已 100% 动用于一般营运资金。 Source: annual report 2024, page 67; annual report 2025, page 70.出处：2024 年年报第 67 页；2025 年年报第 70 页。 | Fully utilised已全数动用 |
| Management was anticipating continued positive contribution of medical devices in 2025.管理层预期医疗器械在 2025 年将继续带来正面贡献。 | In 2025, the medical devices segment delivered positive contributions, and a medical devices corporation accounted for approximately 50% of group turnover.2025 年，医疗器械部门如期带来正面贡献，一家医疗器械公司约占集团总营业额的 50%。 Source: annual report 2024, page 14; annual report 2025, pages 12, 15.出处：2024 年年报第 14 页；2025 年年报第 12、15 页。 | Delivered已达成 |
What the reports leave open年报留下待看的事
- Whether the remaining RM14.24 million of proceeds from the 2022 land disposal is utilised for business or production facility expansion before the extended deadline of 3 November 2026.2022 年土地脱售所得款项中剩余的 RM14.24 million 是否会在延期至 2026 年 11 月 3 日的期限前用于业务或生产设施扩建。
Source: annual report 2025, page 69.出处：2025 年年报第 69 页。
- The financial recovery and scaling up of larvae breeding at associate Ento-Feed, following an impairment loss of RM1.444 million on the loan provided to it in 2025.联营公司 Ento-Feed 在 2025 年其所获贷款被计提 RM1.444 million 减值亏损后，幼虫养殖能否按计划扩大规模并恢复财务表现。
Source: annual report 2025, pages 13, 15.出处：2025 年年报第 13、15 页。
- Fulfillment of confirmed orders of approximately RM10 million scheduled for 2026 in the medical devices segment amid continued softer demand in the automated test equipment market.在自动化测试设备市场需求持续疲软之际，医疗器械部门预定于 2026 年交付的约 RM10 million 确认订单的履行情况。
Source: annual report 2025, page 14.出处：2025 年年报第 14 页。
- The completion of the proposed disposal of a unit of shop-office measuring approximately 98 square meters in Mukim 12, Daerah Barat Daya under the agreement entered into on 2 April 2026.根据 2026 年 4 月 2 日签订的买卖协议，拟脱售 Mukim 12, Daerah Barat Daya 面积约 98 平方米的店屋办公室的完成情况。
Source: annual report 2025, page 77.出处：2025 年年报第 77 页。
Facts as printed in the company's annual reports, with the page of each; no rating and no advice. Built 2026-10-28.内容为公司年报所印的事实，并注明页码；不评级，不构成投资建议。生成日期 2026-10-28。